

Pretox CHLORPYRIFOS D.D.V.P. MC



A. It is a trade name registered in the United States Patent Office.

ACTIVE INGREDIENTS

Chlorpyrifos [0,0-diethyl 0-(3,5,6-Trichloro-2-Pyridyl) phosphorothioate]	15.00
2,2-Dichlorovinyl Dimethyl Phosphate	13.95
Related Compounds	1.05
Aromatic Petroleum Derivative Solvent	69.03
INERT INGREDIENTS	0.97
TOTAL	100.00

**PRECAUTIONARY STATEMENTS
HAZARDS TO HUMANS AND
DOMESTIC ANIMALS**

DANGER

... ..

ENVIRONMENTAL HAZARDS

... ..

PHYSICAL OR CHEMICAL HAZARDS

... ..

KEEP OUT OF REACH OF CHILDREN

**POISON
DANGER**

Statement of Practical Treatment

If swallowed—

If inhaled—

If on skin—

If in eyes—

NOTE TO PHYSICIAN

WARNING SYMPTOMS: Symptoms include weakness, headache, dizziness, chest burning, salivation, blurred vision, pupillary miosis, sweating, nausea, vomiting, diarrhea and abdominal cramps.

TREATMENT: Atropine is the specific therapeutic antagonist of cholinergic agents; it is a muscle relaxant, a nervous system stimulant, a bronchodilator, a sympatholytic and a parasympathetic stimulant. Atropine should be administered at 1 to 2 mg intravenously or 1 to 2 mg orally. If complete Atropine antagonism has occurred, 1 to 2 mg of Atropine should be administered intravenously. Clear chest by postural drainage. Repeat dose if there is a marked increase in vital signs, without warning, cause prolonged susceptibility to very small doses of atropine. Repeat dose if there is a marked increase in vital signs, without warning, cause prolonged susceptibility to very small doses of atropine. Repeat dose if there is a marked increase in vital signs, without warning, cause prolonged susceptibility to very small doses of atropine.

E.P.A. REG. NO. 655-671 E.P.A. EST. NO. 655-NJ-1

NET CONTENTS _____ LOT NO _____

Manufactured by

prentiss Plant: 338 Wilson Avenue
 Newark, N.J. 07105
 Drug & Chemical Co., Inc. Office: 363 7th Avenue
 New York, N.Y. 10001